INmune Bio (NASDAQ:INMB) Stock Rating Upgraded by Wall Street Zen

INmune Bio (NASDAQ:INMB) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Sunday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of INmune Bio in a report on Thursday, June 11th. One analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

INmune Bio Price Performance

INMB traded up $0.15 on Friday, hitting $1.94. The company had a trading volume of 1,590,920 shares, compared to its average volume of 1,300,955. The firm has a market capitalization of $51.57 million, a P/E ratio of -1.16 and a beta of 0.97. The stock has a fifty day simple moving average of $1.46 and a 200-day simple moving average of $1.44. INmune Bio has a 52-week low of $1.09 and a 52-week high of $3.24.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Quadrature Capital Ltd purchased a new stake in INmune Bio in the fourth quarter worth approximately $26,000. Intech Investment Management LLC purchased a new stake in INmune Bio during the 2nd quarter valued at $26,000. Squarepoint Ops LLC bought a new position in shares of INmune Bio during the 3rd quarter valued at $30,000. Virtu Financial LLC bought a new position in shares of INmune Bio during the 4th quarter valued at $32,000. Finally, Wells Fargo & Company MN boosted its stake in shares of INmune Bio by 79.0% in the 4th quarter. Wells Fargo & Company MN now owns 24,857 shares of the company’s stock worth $39,000 after buying an additional 10,970 shares during the last quarter. 12.72% of the stock is owned by hedge funds and other institutional investors.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.